Chester County News and Community Website
WILMINGTON, DE — AstraZeneca’s experimental antibody-drug conjugate sonesitatug vedotin improved overall survival in a Phase III trial of previously treated CLDN18.2-positive advanced gastric and related cancers, potentially broadening targeted treatment …
AstraZeneca Drug Extends Survival in Advanced Gastric Cancer Read More
WILMINGTON, DE — Incyte Corp. (Nasdaq: INCY) will present early clinical data on two cancer treatments that have advanced into Phase 3 testing at the ESMO Congress in Madrid this …
Incyte Advances Two Cancer Drugs as ESMO Congress Nears Read More
CONSHOHOCKEN, PA — Cencora has entered an agreement with Kite, a unit of Gilead Sciences, to distribute two FDA-approved CAR T-cell cancer therapies across a growing network of treatment centers, …
Cencora, Kite Expand CAR-T Distribution Network as Access Grows Read More
WILMINGTON, DE — AstraZeneca has secured U.S. regulatory approval for IMFINZI (durvalumab) in combination with Bacillus Calmette-Guérin (BCG) therapy for adults with previously untreated high-risk non-muscle-invasive bladder cancer, expanding the …
AstraZeneca Wins FDA Approval for IMFINZI in Early Bladder Cancer Read More
PLYMOUTH MEETING, PA — The National Comprehensive Cancer Network has launched a free weekly email service that alerts users to changes in its widely used cancer treatment guidelines, expanding access …
NCCN Launches Weekly Cancer Guideline Alerts for Clinicians Read More WILMINGTON, DE — AstraZeneca said new Phase III cancer and rare disease data presented at the American Society of Clinical Oncology annual meeting could strengthen the company’s position in several …
AstraZeneca Highlights Late-Stage Cancer, Rare Disease Data at ASCO Read More WILMINGTON, DE — AstraZeneca (LSE/STO/NYSE: AZN) reported positive Phase III trial results showing its immunotherapy IMFINZI combined with enfortumab vedotin improved survival outcomes for certain muscle-invasive bladder cancer patients unable …
AstraZeneca Trial Extends Survival in Bladder Cancer Study Read More
WASHINGTON, D.C. — The U.S. Food and Drug Administration has approved Bizengri for adults with advanced NRG1 fusion-positive cholangiocarcinoma, marking the first approved treatment for the rare bile duct cancer …
FDA Approves Bizengri for Rare Bile Duct Cancer Read More
PHILADELPHIA, PA — Dispatch Bio said it will present new preclinical data on its SEND T cell engineering platform at the ASGCT 2026 Annual Meeting, highlighting experimental results showing anti-tumor …
Dispatch Bio Reports Preclinical Cancer Therapy Data Read More
HARRISBURG, PA — A $450 million investment to build a new pharmaceutical manufacturing facility in Philadelphia is expected to create 225 jobs and expand the production of materials used in …
$450M Pharma Plant to Bring Jobs, Cancer Research to Philly Read More